Platelet function, coagulopathy, and impaired fibrinolysis in diabetes

Burton E Sobel1, David J Schneider

  • 1Department of Medicine, University of Vermont, Colchester Research Facility, 208 South Park Drive, Colchester, VT 05446, USA. burt.sobel@vtmednet.org

Cardiology Clinics
|October 27, 2004
PubMed

Insights

Diabetes and metabolic syndrome create a hyper-coagulable state, increasing risks for atherosclerosis and heart disease due to blood clotting issues. Understanding these mechanisms is key to managing cardiovascular complications in patients.

Area of Science:

  • Cardiovascular Medicine
  • Metabolic Disorders
  • Hematology

Background:

  • Diabetes mellitus and metabolic syndrome are characterized by a hyper-coagulable state.
  • Key features include increased platelet reactivity, enhanced coagulation system activity, and impaired fibrinolysis.
  • These hemostatic abnormalities are well-characterized and contribute significantly to disease pathology.

Purpose of the Study:

  • To summarize the pro-thrombotic mechanisms associated with diabetes and metabolic syndrome.
  • To highlight the contribution of these mechanisms to accelerated atherosclerosis and cardiovascular disease.
  • To underscore the clinical significance of understanding these hemostatic derangements.

Main Methods:

  • Review of existing literature on coagulation and fibrinolysis in diabetes and metabolic syndrome.
  • Analysis of characteristic features of hyper-coagulability in these conditions.
  • Synthesis of data linking hemostatic changes to clinical outcomes.

Main Results:

  • Diabetes and metabolic syndrome demonstrably increase blood coagulability.
  • Elevated platelet activity, augmented coagulation factors, and reduced fibrinolytic capacity are consistently observed.
  • These alterations are understood to a significant extent.

Conclusions:

  • The pro-thrombotic state in diabetes and metabolic syndrome is a major contributor to premature cardiovascular disease.
  • Understanding these mechanisms is crucial for mitigating the profound cardiovascular toll associated with these metabolic disorders.
  • Targeting hemostatic pathways may offer therapeutic strategies for affected patients.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Diabetic Foot Ulcer01:31

Diabetic Foot Ulcer

Definition A diabetic foot ulcer (DFU) is a chronic, non-healing wound that develops in individuals with diabetes. It typically occurs on pressure-bearing areas such as the heel, metatarsal heads, or hallux, and carries a high risk of infection and amputation.Pathophysiology • The development of DFUs can be explained by four interconnected mechanisms: neuropathy, ischemia, infection, and impaired wound healing. • Neuropathy is the most common factor. Sensory neuropathy reduces pain perception,...
Coagulation01:09

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...